MX395186B - Vacuna de hpv para su uso en el tratamiento de cáncer de piel. - Google Patents

Vacuna de hpv para su uso en el tratamiento de cáncer de piel.

Info

Publication number
MX395186B
MX395186B MX2017005418A MX2017005418A MX395186B MX 395186 B MX395186 B MX 395186B MX 2017005418 A MX2017005418 A MX 2017005418A MX 2017005418 A MX2017005418 A MX 2017005418A MX 395186 B MX395186 B MX 395186B
Authority
MX
Mexico
Prior art keywords
cancer
skin lesion
lesion treatment
cell carcinoma
hpv
Prior art date
Application number
MX2017005418A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005418A (es
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of MX2017005418A publication Critical patent/MX2017005418A/es
Publication of MX395186B publication Critical patent/MX395186B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2017005418A 2014-10-24 2015-10-23 Vacuna de hpv para su uso en el tratamiento de cáncer de piel. MX395186B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (2)

Publication Number Publication Date
MX2017005418A MX2017005418A (es) 2017-11-30
MX395186B true MX395186B (es) 2025-03-21

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005418A MX395186B (es) 2014-10-24 2015-10-23 Vacuna de hpv para su uso en el tratamiento de cáncer de piel.

Country Status (15)

Country Link
US (1) US10238729B2 (enExample)
EP (1) EP3209676A4 (enExample)
JP (1) JP6663438B2 (enExample)
KR (1) KR102285401B1 (enExample)
CN (1) CN107001430A (enExample)
AU (1) AU2015335652B2 (enExample)
BR (1) BR112017008280A2 (enExample)
CA (1) CA2965498A1 (enExample)
CL (1) CL2017001008A1 (enExample)
IL (1) IL251825B2 (enExample)
MX (1) MX395186B (enExample)
MY (1) MY195018A (enExample)
PH (1) PH12017500754A1 (enExample)
SG (1) SG11201703262UA (enExample)
WO (1) WO2016065281A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO2018009205A2 (es) * 2016-02-27 2018-09-20 Hpvvax Llc Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
US9149503B2 (en) * 2009-04-10 2015-10-06 The Johns Hopkins University Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
PL2444103T3 (pl) 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
AU2010264695A1 (en) * 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
US8809562B2 (en) * 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2014331654A1 (en) 2013-10-13 2016-05-12 The Board Of Trustees Of The University Of Arkansas Human papilloma virus therapeutic vaccine

Also Published As

Publication number Publication date
MY195018A (en) 2023-01-03
WO2016065281A1 (en) 2016-04-28
US20160114023A1 (en) 2016-04-28
JP6663438B2 (ja) 2020-03-11
BR112017008280A2 (pt) 2018-01-02
CL2017001008A1 (es) 2017-11-24
EP3209676A1 (en) 2017-08-30
SG11201703262UA (en) 2017-05-30
KR20170072279A (ko) 2017-06-26
EP3209676A4 (en) 2018-03-28
KR102285401B1 (ko) 2021-08-02
US10238729B2 (en) 2019-03-26
CN107001430A (zh) 2017-08-01
MX2017005418A (es) 2017-11-30
CA2965498A1 (en) 2016-04-28
IL251825B1 (en) 2023-05-01
AU2015335652A1 (en) 2017-05-25
JP2017531699A (ja) 2017-10-26
IL251825B2 (en) 2023-09-01
AU2015335652B2 (en) 2020-07-02
IL251825A0 (en) 2017-06-29
PH12017500754A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
HK1258921A1 (zh) Flt3 定向 car 细胞免疫疗法
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
HK1246183A1 (zh) Hpv疫苗
WO2016160622A3 (en) Hla-g as a novel target for car t-cell immunotherapy
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
NZ746338A (en) Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same
WO2014153082A3 (en) Systems and methods for treating prostate cancer
MY189713A (en) Duocarmycin adcs for use in treatment of endometrial cancer
HK1248588A1 (zh) 用於癌症治疗中的天花疫苗
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2017004660A (es) 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores.
MX2024014239A (es) Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer
MX2017015896A (es) Agente anticancerigeno.
HK1258319A1 (zh) 癌症疗法
EP4552698A3 (en) Methods of treating prostate cancer
IN2014MU00303A (enExample)
EP3998341A3 (en) Adenoviral vectors
MX2017006076A (es) Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
MX2019013862A (es) Terapia de combinacion.
MY194694A (en) Method and composition for treating cancer or skin lesion using a vaccine
PH12017500754A1 (en) Cancer and skin lesion treatment